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AnesthesiaPharmacological preconditioning limits myocardial infarct size after ischemia/reperfusion. Dexmedetomi-
dine is an α2-adrenergic receptor agonist used in anesthesia that may have cardioprotective properties
against ischemia/reperfusion injury. We investigate whether dexmedetomidine administration activates car-
diac survival kinases and induces cardioprotection against regional ischemia/reperfusion injury. In in vivo and
ex vivo models, rat hearts were subjected to 30 min of regional ischemia followed by 120 min of reperfusion
with dexmedetomidine before ischemia. The α2-adrenergic receptor antagonist yohimbine was also given
before ischemia, alone or with dexmedetomidine. Erk1/2, Akt and eNOS phosphorylations were determined
before ischemia/reperfusion. Cardioprotection after regional ischemia/reperfusion was assessed from infarct
size measurement and ventricular function recovery. Localization of α2-adrenergic receptors in cardiac tissue
was also assessed. Dexmedetomidine preconditioning increased levels of phosphorylated Erk1/2, Akt and
eNOS forms before ischemia/reperfusion; being signiﬁcantly reversed by yohimbine in both models. Dexme-
detomidine preconditioning (in vivo model) and peri-insult protection (ex vivo model) signiﬁcantly reduced
myocardial infarction size, improved functional recovery and yohimbine abolished dexmedetomidine-
induced cardioprotection in both models. The phosphatidylinositol 3-kinase inhibitor LY-294002 reversed
myocardial infarction size reduction induced by dexmedetomidine preconditioning. The three isotypes of
α2-adrenergic receptors were detected in the whole cardiac tissue whereas only the subtypes 2A and 2C
were observed in isolated rat adult cardiomyocytes. These results show that dexmedetomidine precondition-
ing and dexmedetomidine peri-insult administration produce cardioprotection against regional ischemia/re-
perfusion injury, which is mediated by the activation of pro-survival kinases after cardiac α2-adrenergic
receptor stimulation.
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rights reserved.1. Introduction
Perioperative cardiac complications such as myocardial ischemia and
infarction are the predominant causes of morbidity and mortality in pa-
tients undergoing noncardiac surgery [1,2]. In order to decrease the inci-
dence of cardiovascular complications in high risk surgical patients,
perioperative administration of cardioprotective drugs is recommended,
but this intervention is still controversial [3,4]. A diverse variety of phar-
macological agents induce intrinsic protective mechanisms against car-
diac ischemia and reperfusion (I/R) injury in animal models [5,6]. This
pharmacological-induced cardioprotection relies on the activation of
pro-survival protein kinases in both a receptor andnon-receptormediat-
ed manner [6]. These kinases, including Akt and Erk1/2 among others,
confer powerful cardioprotection when they are activated during pre-
conditioning phase and at reperfusion [7,8].
Fig. 1. Experimental protocol in vivo and ex vivo models. Rat hearts were subjected to a 30 min anterior descending coronary artery occlusion and 120 min of reperfusion. Control:
no preconditioning, DEX: 10 nM dexmedetomidine preconditioning (25 min), YOH: 1 μM yohimbine preconditioning (30 min), YOH/DEX: 1 μM YOH (30 min) and 10 nM dexme-
detomidine preconditioning (25 min). LY: 20 μM LY-294002 preconditioning (30 min), LY/DEX: 20 μM LY-294002 (30 min) and 10 nM dexmedetomidine preconditioning
(25 min). White arrow shows the sample taking time-point for Western blot analysis. Black arrow shows the measurement time-point of recovery hemodynamic data and myo-
cardial infarction size.
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renergic receptor agonist used in anesthesia. Clinical evidence sug-
gests that induced autonomic nervous system modulation during
perioperative administration of DEX is associated with a trend to-
wards improved cardiac outcomes following noncardiac surgery
[9,10]. Previous experiments in animals have shown beneﬁts of DEX
administration in the ischemic heart [11,12]. Okada et al. showed car-
dioprotective effects in global ischemia of isolated rat hearts [13].
However, perioperative myocardial ischemia and infarction are limit-
ed to a region of hypoperfused myocardium. Currently, if DEX has
preconditioning action against regional I/R injury remains to be fur-
ther investigated as well as whether DEX causes activation of signal-
ing pathways associated with cardiac survival. Accordingly, we
hypothesize that DEX induces heart preconditioning throughout acti-
vation of cardioprotective signaling pathways by cardiac α2-adrener-
gic receptor stimulation, independently from autonomic nervous
system modulation.
To test our hypothesis we study: a) the effect of DEX on phosphory-
lated and total levels of Erk 1/2, Akt and eNOS before regional ischemia
as well as left ventricular (LV) function recovery and infarct size reduc-
tion in the area at risk (AAR) of regional ischemia after reperfusion in
the in vivo and ex vivo models; b) the contribution of DEX-induced
PI3K/Akt signaling pathway activation to cardioprotection in an ex
vivo model; c) the presence and localization of α2-adrenergic
receptors in the rat heart.2. Materials and methods
2.1. Animals and surgical procedures
This study conformed to the Guide for the Care and Use of Labora-
tory Animals, published by the U.S. National Institutes of Health (NIH,
Publication No. 85-23, revised in 1996), and was approved by the In-
stitutional Ethics Review Committee, University of Chile. All experi-
ments were conducted in both in vivo and ex vivo heart models of
adult, male Sprague–Dawley rats (300 g). Dexmedetomidine was
purchased from Hospira Chile (Santiago, Chile).
In vivo model: The rats were anesthetized with pentobarbital
(80 mg/kg IP). The trachea was intubated with a 16-gauche cannula
and connected to a rodent ventilator (Harvard Rodent Ventilator
Model 683, Holliston, MA). Rats were ventilated with O2 enriched
room air at 40–50 breaths/min, with tidal volumes set to 1 ml/
100 mg body weight. Body temperature was kept at a constant
37 °C by using an adjustable heating pad. The right carotid artery
was cannulated with a 24-gauge catheter connected to a ﬂuid-ﬁlled
pressure transducer to continuously monitor systolic, diastolic and
mean arterial pressure (MAP) and heart rate (HR) using a Dash
1000 General Electric monitor. An intravenous 24-gauche catheter
was then installed in the left jugular vein for drug administration.
Subsequently the chest was opened via a left thoracotomy through
the fourth or ﬁfth intercostal space, the ribs were gently retracted
Fig. 2. Dexmedetomidine stimulates Erk 1/2, Akt and eNOS phosphorylation, which is inhibited by yohimbine.Western blots andmean value levels of p-Erk 1/2 at Thr202/Tyr204 , p-Akt at
Ser473 and p-eNOS at Ser1177 in ventricular homogenate in the Control, dexmedetomidine (DEX), yohimbine (YOH) and YOH/DEX groups before ischemia in the in vivo (panel a) and the
ex vivomodel (panel b). p-Erk 1/2, p-Akt and p-eNOS levels were enhanced in the DEX group compared to the other groups in both models. Values are shown as mean±SEM, n=8 per
group in each model, *Pb0.05 DEX vs Control, YOH and YOH/DEX. Data were analyzed by one-way ANOVA and Tukey's multiple comparison test.
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assess temporary regional ischemia of the left ventricle, a 6-0 prolene
loop was placed below the emergence of the ﬁrst branch of the ante-
rior descending coronary artery (ADCA) and the ends of the suture
were threaded through polyethylene tubing (PE-50) to form a snare
for reversible occlusion. After the infusion of study drugs and before
the onset of ischemia heparin 100 U/kg IV was administered. Thenhearts were subject to 30 min of regional ischemia followed by
120 min of reperfusion of the AAR (ADCA dependent territory). Ische-
mia was conﬁrmed by cyanosis on the myocardial surface. Reperfu-
sion was indicated by an epicardial hyperaemic response and rapid
disappearance of cyanosis.
Ex vivo model: the rats were anesthetized with pentobarbital
(80 mg/kg IP). Subsequently, a sternotomy was performed and
Fig. 3. Dexmedetomidine induces cardioprotection against regional ischemia and reperfusion (I/R) injury. The means of myocardial infarction size in the Control, DEX, YOH, YOH/
DEX groups after I/R in the in vivo (panel a) and in the Control, DEX, YOH, YOH/DEX, LY, LY/DEX groups after I/R in the ex vivomodel (panel b). One-way ANOVA revealed that DEX
resulted in a signiﬁcant reduction of infarct size compared to the other groups in both models. Values are shown as mean±SEM, n=8 per group, *Pb0.05 DEX vs. Control, YOH and
YOH/DEX at the end of reperfusion. Data were analyzed by one-way ANOVA and Tukey's multiple comparison test.
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cised, mounted in a temperature regulated heart chamber and
perfused retrograde via the ascending aorta using a peristaltic in-
fusion pump (Gilson Minipuls3, France) at a constant ﬂow of
10–14 ml/min to generate an initial mean coronary (aortic) perfusion
pressure (CPP) of 60–70 mmHg with physiological modiﬁed Krebs
Henseleit Buffer solution containing (in mM) NaCl (128.3), KCl (4.7),
CaCl2 (1.35), NaHCO3 (20.2), NaH2PO4 (0.4), MgSO4 (1.1), glucose
(11.1), pH 7.4 at 37 °C when equilibrated with a mixture of 95% O2 /
5% CO2. Perfusate and bath temperatures were maintained at 37 °C by
a thermostatically controlled water circulator (B. Braun Thermomix
1420, Germany). Then, a latex balloon inserted in the left ventricle
through the mitral valve, was connected to a pressure transducer
(Bridge Amp ML221 AD Instruments, Australia) and ﬁlled with normal
saline to produce a left ventricle end-diastolic pressure (LVEDP) of
5–10 mmHg. The volume of the balloon was maintained constant
throughout the experiment. In order to assess temporary regional is-
chemia of the left ventricle, a 6-0 prolene loop was placed below the
emergence of the ﬁrst branch of the anterior descending coronary ar-
tery (ADCA) and the ends of the suturewere threaded through polyeth-
ylene tubing (PE-50) to form a snare for reversible occlusion. After
15 min stabilization, hearts with a LVDP less than 60 mmHg and a
heart rate (HR) less than 180 bpm, were excluded from the study. The
remaining hearts were subject to 30 min regional ischemia followed
by 120 min reperfusion of the AAR (ADCA dependent territory).
2.2. Experimental protocols
To determine whether DEX induces survival kinases activation,
cardioprotection by α2-adrenergic receptor stimulation independent-
ly from autonomic nervous system modulation and to explore therelationship between DEX induced survival PI3K/Akt pathway activa-
tion and cardioprotection, rats were randomly assigned to one of the
following groups, after 15 min stabilization period and before region-
al ischemia, in each model (Fig. 1).
In vivo model: a) Control group: no preconditioning (30 min ad-
ministration of physiological solution); b) DEX group: precondition-
ing by 10 min bolus administration of 1 μg/kg DEX, followed by
15 min administration of 0.7 μg/kg/h DEX; c) yohimbine (YOH)
group: preconditioning by 5 min bolus administration of 1 mg/kg
YOH, followed by 20 min administration of 0.5 mg/kg/h YOH; d)
YOH/DEX group: preconditioning by 5 min bolus administration of
1 mg/kg YOH, followed by 25 min administration of 0.5 mg/kg/h
YOH. After 5 min into YOH , 10 min bolus administration of 1 μg/kg
DEX followed by 15 min administration of 0.7 μg/kg/h DEX.
Ex vivo model: a) Control group: no preconditioning (30 min ad-
ministration of buffer solution); b) DEX group: preconditioning by
25 min administration of 10 nM DEX in modiﬁed Krebs Henseleit
Buffer solution, followed by 5 min washout; c) YOH group: precondi-
tioning by 30 min administration of 1 μM YOH in buffer solution, fol-
lowed by 5 min washout; d) YOH/DEX Group: preconditioning by
30 min administration of 1 μM YOH in buffer solution and after
5 min into YOH, 25 min administration of 10 nM DEX in buffer solu-
tion, followed by 5 min washout; e) LY group: preconditioning by
30 min administration of 20 μM LY-294002 in buffer solution, fol-
lowed by 5 min washout; f) LY/DEX Group: preconditioning by
30 min administration of 20 μM LY-294002 in buffer solution and
after 5 min into LY, 25 min administration of 10 nM DEX in buffer so-
lution, followed by 5 min washout.
The dose of DEX in the in vivo and in the ex vivo models was used
according to the manufacturer’s recommendation and Okada et al.
[13], respectively.
Fig. 4. Dexmedetomidine preconditioning improves LV functional recovery after I/R injury. The means of hemodynamic measures (LVDP, LVEDP, +dP/dtmax,−dP/dtmin, HR and
CPP), before preconditioning and at the end of 2 h reperfusion in the ex vivo model. ANOVA (mixed model) revealed that compared to other groups DEX group showed improved
LVDP and improved +dP/dtmax and−dP/dtmin, at the end of reperfusion. Values are expressed as mean±SEM, n=8 per group, *Pb0.05 DEX vs Control, YOH, YOH/DEX, LY and
LY/DEX, at the end of reperfusion in ex vivo model. #Pb0.05 basal vs end of reperfusion. Data were analyzed by ANOVA for repeated measurements and Bonferroni multiple com-
parisons test.
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In both models, at the end of the reperfusion, the ADCA was again
occluded and the AAR was delineated by Evans blue staining of the
non-ischemic myocardium. Whether the hearts were rapidly excised
from the thoracic cavity in the in vivomodel or were unmounted from
the Langendorff system, the atria and great vessels were separated
from ventricles. They were sliced from the base to the tip into 2 mm
slices. The slices were then counterstained with 15 ml 2,3,5-triphe-
nyltetrazolium chloride 1% (Sigma Chemical) in phosphate buffer ad-
justed to pH 7.4, for 15 min at 37 °C. After overnight storage in 10%
formaldehyde, slices were placed on a Plexiglas holder and covered
by a glass. Two-millimeter shims in the corners hold the glass awayfrom the bottom sheet by the desired slice thickness. Spring clamps
were used to press the glass down against the shims, squashing the
slices to a uniform 2 mm. Then, a digital photography of the mounted
tissue was taken. For each slice, measuring the size of the AAR and in-
farct area was performed by planimetry using the Image J program
[14]. The AAR was expressed as a percentage of the ventricles volume,
and infarct size was expressed as a percentage of the AAR.
2.4. Measurement of LV function
The LV function was only determined in the ex vivo model. The
LVEDP, left ventricle peak systolic pressure (LVSP), the maximal positive
and negative peak of ﬁrst derivative of LV pressure (+dP/dtmax, −dP/
Fig. 5. Characterization of α2-adrenergic receptors in the heart. a. Western blot showing speciﬁc α2A, α2B and α2C adrenergic receptor subtypes expression in Sprague–Dawley rat
cardiac tissues homogenate. H, whole adult hearts. CM, adult cardiomyocytes. Immunoblotting was performed as described in Materials and methods. Molecular size marker is in-
dicated on the left. b. Ventricle sections from adult Sprague–Dawley rats were immunostained for α2A-adrenergic receptors antibody (1:500) (panels D, E, F), α2B-adrenergic re-
ceptors antibody 1:500 v/v (G,H,I) and α2C-adrenergic receptors antibody 1:500 v/v (J, K, L). All controls (no primary antibody) were negative (A, B, C). Black arrows indicate
the immunodetection of α2-adrenergic receptors. Heart sections were processed for routine immunoperoxidase techniques and counterstained with Mayer’s hematoxylin. Bar
scale: 20 μm. Data showed are representative ﬁgures of 5 animals.
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recorded throughout the entire experiment on a personal computer
using PowerLab (ML866 ADInstruments, Australia). LV developed pres-
sure (LVDP) was calculated as follow: LVDP=LVSP−LVEDP (mmHg).
2.5. Western blot analysis
The levels of total and phosphorylated forms of Erk 1/2, Akt and
eNOS in whole adult rat cardiac tissue and the presence of the α2-ad-
renergic receptor subtypes in whole adult rat cardiac tissue and iso-
lated adult rat cardiomyocytes were determined by Western blot
analysis. To this end, the hearts from each animal and isolated adult
cardiomyocytes were frozen in liquid nitrogen. Cardiac tissues were
homogenized in iced-cold buffer containing phosphatase and prote-
ase inhibitors (in mM): Tris–HCl (50), NaCl (150), EDTA (1), Na3V04
(5), NaF (20), Na4P2O7 (10), Nonidet P-40 1%(v/v) and a protease in-
hibitor cocktail (Roche Diagnostics, Mannheim, Germany), ﬁnal pH
7.4 [15]. For electrophoresis and Western blot analysis, tissue protein
lysates were matched for proteins (30 μg) and separated by sodium
dodecil sulphate-polyacrilamide gel electrophoresis (SDS-PAGE) 8%
and transferred to PVDF membranes (Millipore Corp., Bedford, MA).
Blots were probed with antibodies raised against p-AktSer473, total
Akt, p-ERK1/2Thr202/Tyr204, total ERK 1/2 (Cell Signaling TechnologyInc. New England, NY, USA), p-eNOSSer1177 and total eNOS (BD Trans-
duction Laboratories, NJ, USA), α2A adrenergic receptor (Antibodies
online.com, Aachen, Germany) or α2B and α2C adrenergic receptors
(Thermo Fisher Scientiﬁc Inc. Rockford, IL, USA). After an additional
incubation period with appropriate horseradish peroxidase-linked
secondary antibodies (Calbiochem, San Diego, CA), immunoreactivity
was visualized by a peroxidase-based chemiluminescence detection
kit, ECL plus (Amersham Biosciences, Pittsburgh, PA). The signal in-
tensity of the bands in the immunoblots was quantiﬁed by densitom-
etry using the software Image J [14].
2.6. Immunohistochemistry
The localization of α2-adrenergic receptor subtypes in the adult
rat heart was determined by immunohistochemistry. To this end,
rat hearts were ﬁxed in 4% formaldehyde in 0.1 M phosphate buffer
(pH 7.3) for 24 h, dehydrated in alcohol, clariﬁed in xylene, embed-
ded in parafﬁn wax and cut into 5 μm sections. Standard immunoper-
oxidase techniques were employed to detect α2A, α2B and α2C
adrenergic receptors. The corresponding antibody against the α2A,
α2B and α2C adrenergic receptors (1:500) was applied to each individ-
ual section at 4 °C overnight. Immunostaining was performed using
an HRP-labelled streptavidin biotin kit (RTU-Vectastain kit)
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with Mayer’s hematoxylin (DAKO, Carpinteria, CA) and mounted with
Entellan (Merck, Santiago, Chile). Immunohistochemical controls were
done by replacing the primary antibody with phosphate buffered
saline. All controls were negative. All sections were examined by light
microscopy (Leitz, Orthoplan) and images were captured with a
Canon 1256 camera.2.7. Statistical analysis
The sample size for these experiments was deﬁned in 8 animals
per group in each model. Levels of survival kinase phosphorylation
after pharmacological preconditioning and the size of risk and infarct
areas at the end of reperfusion were analyzed using one-way ANOVA.
A Tukey post-hoc test was used to assess the activation and precondi-
tioning effect differences among groups. Hemodynamic data at differ-
ent times were analyzed with repeated-measures two-way ANOVA
(mixed model). Bonferroni post-hoc test was used to assess the recov-
ery differences among groups. A value of Pb0.05 was considered sig-
niﬁcant. All data are expressed as mean±SEM.3. Results
3.1. Dexmedetomidine stimulates Erk 1/2, Akt, eNOS signaling pathways
in an in vivo and ex vivo model of I/R injury
Fig. 2a–b shows representative Western blots and mean values of
the ventricular levels of phosphorylated Erk 1/2, Akt and eNOS in
Control, DEX, YOH and YOH/DEX groups, after preconditioning and
immediately before ischemia in the in vivo and ex vivo models, re-
spectively. In both models, 25 min of DEX preconditioning resulted
in a signiﬁcant increase in Erk, Akt and eNOS phosphorylation com-
pared to the other three groups. YOH administration did not modify
phosphorylated levels of the three survival proteins compared to
the controls in both models. The DEX-induced increase in Erk, Akt
and eNOS phosphorylation was blunted by the addition of YOH.3.2. Dexmedetomidine preconditioning reduced myocardial infarction
size both in vivo and ex vivo model of I/R injury
The reduction of infarct size in the in vivo and ex vivo models is
shown in Fig. 3a–b, respectively. The AAR as a percent of the ventricles
volume was similar among groups, in both models. DEX precondition-
ing signiﬁcantly reduced infarct size of the AAR compared to the other
groups in the in vivo and the ex vivo models. YOH administration did
not modify the infarct size compared to controls in both models. How-
ever, the DEX-induced reduction in the regional infarction size was
blunted by the addition of YOH in the in vivo (Control: 50±3%, DEX:
22±4%, YOH: 41±2%, YOH/DEX: 32±2%) and in the ex vivo models
(Control: 36±3%, DEX: 8±3%, YOH: 41±6%, YOH/DEX: 30±3%).3.3. Dexmedetomidine preconditioning signiﬁcantly improves LV func-
tional recovery in an ex vivo model of I/R injury
In the ex vivo model, the preconditioning effect with DEX was ev-
ident at the end of reperfusion from an increased recovery of LVDP,
+dP/dtmax and −dP/dtmin compared to the control group. DEX in-
duced improved functional ventricle recovery was abolished by
YOH. LVEDP, HR and CPP were similar among groups throughout
these experiments. LV performance and hemodynamic data in the
ex vivo model are shown in Fig. 4. The effect of time and I/R process
was signiﬁcant in all of the measured variables, but not in the HR.3.4. Role of PI3K signaling in dexmedetomidine preconditioning
PI3K inhibition by LY-294002 precludes the DEX induced reduc-
tion of infarct size in the in vivo model. In this experiment, AAR as a
percent of the ventricles volume was similar among groups. Fig. 3b
shows that DEX preconditioning signiﬁcantly reduced infarct size of
the AAR compared to the other three groups. LY-294002 did not mod-
ify infarct sizes compared to control. However, DEX-induced reduc-
tion in the regional infarct size was blunted by LY-294002 (Control:
36±3%, DEX: 8±3%, LY: 40±4%, LY/DEX: 38±4%).
DEX preconditioning effect on ventricular function was also affect-
ed by LY-294002. In these experiments, DEX increased recovery of
LVDP, +dP/dtmax and −dP/dtmin compared to the control. DEX-
induced improved functional ventricle recovery was also abolished
by LY-294002. LVEDP, HR and CPP were similar among groups. LV
performance and hemodynamic data in the ex vivo model are
depicted in Fig. 4.
3.5. Detection of α2-adrenergic receptors in the rat heart
The α2-adrenergic receptors were studied by Western blot analysis
in whole adult rat cardiac tissue and isolated adult rat cardiomyocytes.
As shown in Fig. 5a, the α2-adrenergic receptor subtypes A, B and C
were observed in the whole cardiac tissue while the isotypes A and C
were detected in isolated adult rat cardiomyocytes. Immunohistochem-
istry analysis of adult ventricular tissue revealed the presence of α2A-
adrenergic receptors in the endothelium of blood vessels and on the
surface of cardiomyocytes (Fig. 5b). The α2B-adrenergic receptors
were detected in the smooth muscle cells of small arterioles and
veins, and the α2C-adrenergic receptors on the surface of cardiomyo-
cytes and in the smooth muscle cells of arterioles (Fig. 5b).
4. Discussion
The main ﬁndings of this study were: a) DEX pretreatment in-
duces Erk 1/2, Akt and eNOS activation, improves myocardial function
and reduces myocardial infarction size after regional I/R of the heart
in the in vivo and ex vivomodels. b) The administration of the α2-ad-
renergic receptor antagonist YOH blocked Erk 1/2, Akt and eNOS
phosphorylation as well as DEX-induced cardioprotection in both
models. c) Also inhibition of PI3K activation and subsequently eNOS
phosphorylation precludes and abolishes cardioprotection induced
by DEX. d) The three isotypes of α2-adrenergic receptors were
detected in the whole cardiac tissue where the α2A and α2C adrener-
gic receptors were detected in isolated cardiomyocytes. Therefore, it
seems likely that independently from autonomic nervous system
modulation, DEX cardioprotective effects are mediated by activation
of pro-survival PI3K/Akt signaling pathway after cardiac α2-adrener-
gic receptor stimulation. However, while the preconditioning exists
based on the ﬁnding of phosphorylation of Erk, Akt and eNOS in
both models, an effective wash out period of DEX in the in vivo
model is difﬁcult to accomplish due to experimental limitations.
Therefore, since DEX requires a complete metabolism to ensure a
purely preconditioning state, a peri-insult protective effect cannot
be ruled out in this model.
The present study shows that DEX preconditioning increases Erk
1/2, Akt and eNOS phosphorylation. From a molecular point of view,
almost every cardioprotective strategy available activates the canon-
ical signaling pathways associated with cell survival [5,6]. Erk, Akt
and eNOS are normally activated during I/R events, but at insufﬁcient
levels to produce cardioprotection. A more powerful stimulus, either
mechanical or pharmacological, is required to confer protection. Sev-
eral agents have shown to confer cardioprotection by binding to their
speciﬁc G-protein coupled receptor. Ligand binding at the G-protein
coupled receptor results in PI3K/Akt and Ras-MEK1-2-Erk1/2 signal-
ing cascades activation [6]. DEX is a known potent agonist of the
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activation of these kinases with DEX preconditioning as we demon-
strated here. The molecular mechanisms involved in the activation of
Erk and Akt downstream of stimulation of α2-adrenergic receptor
linked to adenylil cyclase are still not completely understood. However,
evidences show that some cellular responses to α2-adrenergic receptor
stimulation are mediated by Erk and PI3K/Akt signaling pathways [17–
21]. Interestingly after α2-adrenoceptor stimulation, transactivation of
EGF receptor by different mechanisms depending on the investigated
tissue is responsible for ERK and Akt activation and one key step in
this last effect is the involvement of PI3K activation downstream of
EGF transactivation [17,21]. The mechanism whereby PI3K contributes
to activation of the Erk pathway is unclear and deserves further explo-
ration in the heart. However, the regulation of the Erk signaling cascade
by PI3K has been previously shown for various Gq- or Gi-coupled recep-
tors, includingα2-adrenoreceptor andM3muscarinic receptor [21–23].
The identiﬁcation of EGF receptor/PI3K/Akt/Erk cascade as a signiﬁcant
component of α2-adrenergic receptor signaling in other tissues opens
the possibility that DEX cardioprotective effects against I/R injury
could be triggered by this mechanism. In the other hand, ischemic and
pharmacological preconditioning induces a biphasic response in pro-
survival kinase activation, with the ﬁrst phase occurring immedi-
ately after preconditioning maneuvers and the second phase of ac-
tivation occurring at reperfusion, after the ischemic insult [7,8,24].
Activation of PI3K/Akt/eNOS pathway is required during the pre-
conditioning phase and at reperfusion to mediate induced-
cardioprotection. Previous studies have shown that different survival
pathways exhibit cross talk, with one kinase pathway interacting and
inﬂuencing the activation of another [25]. In this study we explored ac-
tivation of Erk1/2, Akt and eNOS before the I/R insult. Therefore, study-
ing the phosphorylation levels of survival associated kinases after
reperfusion of DEX treated hearts is warranted.
Previous investigation by Okada et al. showed DEX cardioprotec-
tive effects on global ischemia in an isolated rat heart model [13].
They found that DEX administration prior to global ischemia and re-
perfusion decreased coronary ﬂow and decreased myocardial infarct
size. The authors proposed that DEX-induced coronary vasoconstric-
tion by α2-adrenergic receptor stimulation decreased coronary ﬂow,
induced myocardial ischemia and triggered ischemic preconditioning
of the heart. This study showed a reduction in coronary ﬂow, but the
referred myocardial ischemia during DEX administration was never
demonstrated by the authors. Previous work in human volunteers
showed coronary vasoconstriction and reduction of coronary blood
ﬂow, but a parallel reduction of myocardial oxygen demand. No is-
chemic episodes were reported in this trial [26]. In the present
study we did not ﬁnd evidence for myocardial ischemia during DEX
administration. Even though, we did not determine effective coronary
ﬂow, CPP measurements were not signiﬁcantly different from basal
values and were similar among study groups during and after DEX in-
fusion in our ex vivo model. Therefore, the theory that DEX adminis-
tration produces ischemic preconditioning seems less plausible. In
the other hand, since perioperative myocardial ischemic events and
myocardial infarction are regional rather than global, our in vivo and
ex vivo models were chosen to examine the cardioprotective effect
of DEX against regional I/R injury, to explore the underlying mecha-
nism of protection under controlled conditions and to assess the im-
pact of neurohumoral and systemic hemodynamic effects. In this
study, in vivo (preconditioning) and ex vivo (peri-insult protection)
models, showed similar proportion of cardioprotective capacity of
DEX after reperfusion of regional lethal ischemic insult. Prophylactic
administration of DEX reduced the myocardial infarction size in the
risk zone by almost 28% in both models and improved ex vivo recov-
ery of myocardial function. Both DEX-induced beneﬁcial effects on
myocardial infarction size and ventricular function were abrogated
by YOH. This evidence suggests that DEX cardioprotective effects are
mostly mediated by a molecular response within the cardiomyocytesafter α2-adrenergic stimulation rather than exclusively neurohumoral
systemic modulation. In order to conﬁrm the importance of the α2-
adrenergic receptors in the cardioprotection induced by DEX, we
also studied the cardioprotective effect of the α2-adrenergic receptor
agonist xylazine [27]. Our results show that xylazine preconditioning
signiﬁcantly reduced infarct size and improved hemodynamic func-
tion in the ex vivomodel and this effect was also blunted by the addi-
tion of YOH [See Supplemental Materials].
We also study the causal relationship between DEX-induced ki-
nase activation and its preconditioning capacity against regional I/R
injury. Our ﬁndings conﬁrm our hypothesis that DEX induces cardio-
protective signaling activation by cardiac α2-adrenergic receptor
stimulation. In order to demonstrate this link, PI3K inhibition was
used to investigate DEX effects on myocardial function recovery and
reduction of infarct size after regional I/R in the ex vivomodel. The re-
sults demonstrated that PI3K is essential to confer DEX-induced pro-
tection against I/R injury. However we did not inhibit Erk1/2
activation and it will be interesting to explore the role of MEK1/2–
Erk1/2 signaling cascades in DEX preconditioning in future studies.
In the same direction we cannot exclude the involvement of other
known components related to cardioprotection. In neuronal models
some potential antioxidant properties of DEX have been demonstrat-
ed [28]. Therefore, we cannot rule out protective effects of DEX on re-
active oxygen species production. This particular aspect deserves
further exploration in new trials.
The elucidation of DEX induced cardioprotective signaling may
have important implications for the development of perioperative
cardioprotective strategies. In this sense, we also explored the locali-
zation of α2-adrenergic receptor subtypes potentially implicated in
DEX preconditioning. Western blot analysis of whole cardiac tissue
revealed the existence of the three α2-adrenergic receptor subtypes
which agree with previous works in rat and human heart [29–32].
However, studies addressing the localization and distribution of
these receptor subtypes in rat heart are confusing [30,33,34]. Our in-
vestigation conﬁrmed the existence of three α2-adrenergic receptor
subtypes in whole rat cardiac tissue but with a different distribution
pattern for each α2-adrenergic receptor subtype. Western blot analy-
sis of isolated adult rat cardiomyocytes showed the presence of α2A
and α2C-adrenergic receptor subtypes, but not α2B. Our immunohis-
tochemical studies in whole heart also showed α2A and α2C-adrener-
gic receptors in cardiomyocytes. Collectively, these evidences suggest
that stimulation of cardiomyocyte α2A and/or α2C-adrenergic recep-
tors by DEX could activate prosurvival kinases within these cells, pro-
tecting them against I/R injury.
The main limitations of this study were: a) Although DEX admin-
istration induces cardioprotection in the in vivo and ex vivo models,
we did not observe a reduction in the levels of apoptosis in DEX-
treated hearts assessed by caspase 3 levels and TUNEL (data not
shown) under our experimental condition (30 min of regional ische-
mia followed by 120 min of reperfusion). It is possible that 2 h reper-
fusion is a too short period of time to show differences among groups.
Even though, reperfusion appears to accelerate the timing of apopto-
sis in the non-salvageable cells compared with permanent occlusion,
it also lowers the number of cardiomyocytes undergoing apoptosis.
This fact makes that deﬁnitive identiﬁcation of apoptosis in the myo-
cardium remains complex [35–37]. We also investigated whether
DEX could protect cultured neonatal rat cardiomyocytes to simulated
ischemia. Our in vitro results show no protection with DEX (data not
shown). We cannot rule out the possible inﬂuence of not studied mo-
lecular components present in the whole heart that might have en-
hanced or that may be required for DEX induced cardioprotection
[38] and further studies should clarify this point. b) We showed that
DEX preconditioning increased levels of phosphorylated Erk1/2, Akt
and eNOS before I/R; being signiﬁcantly reversed by YOH and demon-
strated the relevance of the PI3K for DEX induced cardioprotection.
However, we did not explore the underlying mechanisms involved
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receptors triggered by DEX. As stated before, transactivation of EGF
receptor could be involved in the activation of both kinases. The role
of ERK on DEX cardioprotection was not studied. Both unsolved prob-
lems deserves further exploration. c) Although our study showed that
DEX preconditioning improves ventricular performance against I/R
events in the ex vivomodel; because of experimental design limitations
we could not determine the ventricular function in the in vivomodel.
The present study shows the cardioprotective properties of DEX
when administered previous to I/R events. Also, it demonstrates acti-
vation of cardiac kinases associated with cellular survival in a
receptor-mediated manner. These facts support the idea that DEX is
not only a useful sedative, but also plays a pivotal role in anesthetic
cardioprotection. While the cardioprotective effects of perioperative
recommended drugs are debated and not well established, research
efforts should be addressed to elucidate unsolved issues of molecular
mechanisms involved in cardioprotection of existing anesthetics. The
potential beneﬁts of DEX preconditioning and peri-insult protection in
high risk cardiovascular patients undergoing surgery are enormous.
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